IPP Bureau
Apollo launches its 76th hospital, boosts tech-led healthcare in India
By IPP Bureau - April 28, 2026
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers
By IPP Bureau - April 28, 2026
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Concept Medical unveils promising 3-year data for sirolimus balloon therapy
By IPP Bureau - April 28, 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Rheumatology Awareness Walkathon 2026 spotlights arthritis and autoimmune care
By IPP Bureau - April 28, 2026
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Biosimilars gain momentum as US market sees 92 approvals: Samsung Bioepis report
By IPP Bureau - April 28, 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
.png "EssilorLuxottica receives FDA authorization for its Essilor Stellest lens for myopia control")
EssilorLuxottica receives FDA authorization for its Essilor Stellest lens for myopia control
By IPP Bureau - April 28, 2026
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
OMRON Healthcare to donate 3,000 blood pressure monitors globally for hypertension screening
By IPP Bureau - April 28, 2026
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
LVPEI launches Eye and Brain Centre in Hyderabad with support from D. E. Shaw India
By IPP Bureau - April 27, 2026
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Indian Immunologicals clocks all-time high revenue of Rs 1,586 crore in FY26
By IPP Bureau - April 27, 2026
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Prof. Gobardhan Das appointed to NITI Aayog; PM Modi commends his contributions to R&D
By IPP Bureau - April 27, 2026
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Sun Pharma to acquire Organon in $11.75 billion all-cash deal
By IPP Bureau - April 27, 2026
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Alembic announces FDA final approval for Fingolimod capsules
By IPP Bureau - April 27, 2026
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Nihilent unveils nSEPIA Beta to turn emotional wellness into measurable science
By IPP Bureau - April 27, 2026
nSEPIA aims to bring structure to an area long dominated by subjectivity
BMS–Pfizer expands Eliquis access through Cost Plus Drug setting $345 monthly price
By IPP Bureau - April 27, 2026
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
Zydus wins DCGI nod to launch Phase III trials of new anti-malarial drug Zintrodiazine
By IPP Bureau - April 27, 2026
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
